Aeolus to develop AEOL 11207 for treatment of central nervous system disorders

By Lisa Kerner

Charlotte, N.C., June 20 - Aeolus Pharmaceuticals, Inc. has selected AEOL 11207 as the first development candidate in its Pipeline Initiative.

Administered orally, AEOL 11207 is readily absorbed and reaches both the circulatory system and the brain in sufficient amounts to demonstrate biological activity, according to a company news release.

Data suggest that AEOL 11207 may be useful as a potential once-every-other-day oral therapeutic treatment option for central nervous system (CNS) disorders, such as Parkinson's disease.

In a widely used animal model of Parkinson's disease, AEOL 11207 crossed the blood brain barrier and protected dopamine neurons in a dose-dependent manner.

Two additional compounds, AEOL 11203 and AEOL 11216, are being evaluated and considered for non-CNS indications.

San Diego-based Aeolus develops disease-modifying compounds for the treatment of central nervous system diseases and for use in oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.